Oncology | Phase I Developments | GERMANY

Medigene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Medigene Enters Phase I Clinical Development with its TCR-T Immunotherapy MDG1021 in Hematological Cancers

Lead Product(s): MDG1021

Therapeutic Area: Oncology Product Name: MDG1021

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

The Phase I study of MDG1021 will be initiated at the Leiden University Medical Center (LUMC), the Netherlands, and will enroll patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation

GEMoaB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meeting II

Lead Product(s): UniCAR-T-CD123

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

The AACR poster presentations highlight GEMoaB's rapidly switchable universal CAR-T platform, UniCAR. The UniCAR platform promises an improved therapeutic window and increased efficacy and safety over conventional CAR-T therapies in hematological malignancies and solid tumors.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting

Lead Product(s): BAY2416964

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2020

Details:

Additional analyses from clinical trials may further aid in identifying the appropriate patients for Vitrakvi®, including a presentation on patient outcomes by prior therapy and performance status .

GEMoaB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GEMoaB Announces First Patient Apheresed in a Phase IA Study

Lead Product(s): UniCAR-T-CD123

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2020

Details:

Apheresed the first patient in a Phase IA study with UniCAR-T-CD123, the lead product candidate from its proprietary UniCAR cellular immunotherapy platform.

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol...

Lead Product(s): BI 1701963

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Boehringer Ingelheim initiates Phase 1 trial for a FORMA-discovered, BI-licensed protein-protein interaction program and BMS initiates Phase 1B trial for FORMA-discovered, Celgene-licensed pan BET inhibitor.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020

Lead Product(s): Regorafenib,Pembrolizumab,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination with immuno-oncology therapies.

Find

Find Oncology Drugs in Phase I Clinical Development in GERMANY

Germany

Product Type

Companies

Medigene

Medigene Enters Phase I Clinical Development with its TCR-T Immunotherapy MDG1021 in Hematological Cancers

GEMoaB

GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meeting II

Bayer HealthCare

Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting

GEMoaB

GEMoaB Announces First Patient Apheresed in a Phase IA Study

Boehringer Ingelheim GmbH

FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol...

Bayer HealthCare

Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020